Literature DB >> 11103877

Animal models for the negative symptoms of schizophrenia.

B A Ellenbroek1, A R Cools.   

Abstract

Negative or defect symptoms refer to a reduction in normal functioning. In schizophrenia, negative symptoms encompass, among others, anhedonia, flat affect, avolition and social withdrawal. These symptoms have been found to be particularly prominent in the more chronic phase of the illness and seem to be virtually insensitive to current antipsychotic treatment. This review focuses on the possibilities and limitations of animal models for the negative symptoms of schizophrenia. Following a review of the negative symptoms in schizophrenia, attention is focused on the two symptoms most often modelled in animals - anhedonia and social withdrawal. We then look at the important question of how to model schizophrenic pathology in animals. Since the exact pathology is still far from clear, most efforts have in the past concentrated on using psychotomimetic drugs such as amphetamine or phencyclidine. The recently accumulated knowledge that schizophrenia probably results from disturbances in the normal development of the brain has led to a surge of new animal models in which the long-term consequences of early manipulations are investigated. However, so far these models have predominantly concentrated on the positive rather than the negative symptoms of schizophrenia. The last part of this review is dedicated to the question of validation of animal models for anhedonia and social withdrawal. The general conclusion is that very few models have so far been adequately tested. The lack of currently effective treatment further hampers the study of such validation.

Entities:  

Mesh:

Year:  2000        PMID: 11103877     DOI: 10.1097/00008877-200006000-00006

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  53 in total

1.  Editorial--modeling negative symptoms: what's missing?

Authors:  Paul D Shepard
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

2.  GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders.

Authors:  Jared W Young; Mary E Kamenski; Kerin K Higa; Gregory A Light; Mark A Geyer; Xianjin Zhou
Journal:  Neuropsychopharmacology       Date:  2015-04-24       Impact factor: 7.853

Review 3.  A review of the discovery, pharmacological characterization, and behavioral effects of the dopamine D2-like receptor antagonist eticlopride.

Authors:  Jennifer L Martelle; Michael A Nader
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

4.  Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

Authors:  Colm M P O'Tuathaigh; Brian P Kirby; Paula M Moran; John L Waddington
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

Review 5.  The transgenerational transmission of childhood adversity: behavioral, cellular, and epigenetic correlates.

Authors:  Nicole Gröger; Emmanuel Matas; Tomasz Gos; Alexandra Lesse; Gerd Poeggel; Katharina Braun; Jörg Bock
Journal:  J Neural Transm (Vienna)       Date:  2016-05-12       Impact factor: 3.575

6.  Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus.

Authors:  Ming Li; Wei He; Alexa Mead
Journal:  Behav Pharmacol       Date:  2009-02       Impact factor: 2.293

7.  NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity.

Authors:  Bo Li; Nino Devidze; Denis Barengolts; Naseem Prostak; Eleana Sphicas; Alfonso J Apicella; Roberto Malinow; Effat S Emamian
Journal:  J Neurosci       Date:  2009-09-23       Impact factor: 6.167

8.  Progressive ratio performance following challenge with antipsychotics, amphetamine, or NMDA antagonists in adult rats treated perinatally with phencyclidine.

Authors:  Jenny L Wiley; Amelia D Compton
Journal:  Psychopharmacology (Berl)       Date:  2004-07-08       Impact factor: 4.530

Review 9.  Consideration of species differences in developing novel molecules as cognition enhancers.

Authors:  Jared W Young; J David Jentsch; Timothy J Bussey; Tanya L Wallace; Daniel M Hutcheson
Journal:  Neurosci Biobehav Rev       Date:  2012-10-12       Impact factor: 8.989

Review 10.  Social stress, therapeutics and drug abuse: preclinical models of escalated and depressed intake.

Authors:  Klaus A Miczek; Jasmine J Yap; Herbert E Covington
Journal:  Pharmacol Ther       Date:  2008-08-15       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.